A visual dosing aid for first-line pediatric antiretroviral treatment in resource-poor settings

Area of Science:

• Pediatric infectious diseases
• Pharmacology
• Global health

Background:

• Accurate dosing is critical for effective pediatric antiretroviral treatment (ART).
• Existing dosing methods may face challenges with children's growth and weight fluctuations.
• The visual dosing aid (VDA) was developed to address these challenges.

Purpose of the Study:

• To assess the theoretical accuracy of the VDA for pediatric ART dosing.
• To compare VDA dosing with World Health Organization (WHO) recommendations.
• To evaluate VDA performance across different populations.

Main Methods:

• Anthropometric data from 55 children in the USA and 324 children in the Democratic Republic of the Congo were used.
• Theoretical accuracy of VDA doses was calculated.
• VDA doses were compared to WHO-recommended doses and generic fixed-dose combination tablets.

Main Results:

• VDA doses closely aligned with WHO-recommended doses.
• Significant dosing differences (>or=20%) were infrequent (<3%) for NVP, AZT, and d4T, but occurred in 20% for 3TC (overdosing more frequent).
• The VDA performed comparably to generic pediatric fixed-dose combination tablets, with no significant differences between study sites.

Conclusions:

• The VDA demonstrates accuracy in calculating pediatric ART doses across diverse populations.
• The VDA can facilitate the accurate dosing of pediatric ART, supporting its implementation in resource-poor settings.